Eli Lilly Invests $9.2M in ProQR as Biotech Raises $50M
PRQR sits 19% above its 52-week low of $1.33 on elevated volume (12× avg).
Summary
ProQR Therapeutics announced a $50 million capital raise through a registered direct offering and private placement. Eli Lilly is a key investor, purchasing 5.1 million shares for approximately $9.2 million at $1.81 per share. This significant financing, representing about 30% of ProQR's market cap, provides crucial funding for R&D and operations. Eli Lilly's investment offers strong external validation for ProQR's technology and pipeline. This follows the positive Phase 1 AX-0810 data announced yesterday, which is reiterated here.
At the time of this announcement, PRQR was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $164.9M. The 52-week trading range was $1.33 to $3.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.